Avalo Therapeutics, Inc. Cash Flow Statement
AVTX|9 years of annual SEC 10-K data (FY2017-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 9 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$51M
FY2025
Free Cash Flow
N/A
FY2025
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Avalo Therapeutics, Inc. used $51M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.59 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -94.2% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$78.3M | -$35.1M | -$31.5M | -$41.7M | -$84.4M | -$63.5M | -$16.1M | -$40.1M | $11.9M |
| Depreciation & Amortization | $344.0K | $169.0K | $158.0K | $166.0K | $1.7M | $1.8M | $3.9M | $4.6M | $425.5K |
| Operating Cash Flow | -$51.5M | -$49.1M | -$30.7M | -$26.8M | -$70.9M | -$40.5M | -$19.1M | -$3.1M | $12.6M |
| Capital Expenditures | - | - | - | $95.0K | $113.0K | $63.0K | $262.0K | $564.4K | $23.3K |
| Free Cash Flow | - | - | - | -$26.8M | -$71.0M | -$40.6M | -$19.4M | -$3.7M | $12.6M |
| FCF Margin | - | - | - | -148.7% | -1315.4% | -606.1% | -287.3% | -52.5% | 45.1% |